Literature DB >> 9723224

High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection.

B D Kahan1.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 9723224     DOI： 10.1016/s0041-1345(98)00737-4

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  4 in total

Review 1.  Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations.

Authors:  María del Mar Fernández De Gatta; Dolores Santos-Buelga; Alfonso Domínguez-Gil; María José García
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Cyclosporine A monitoring--how to account for twice and three times daily dosing.

Authors:  Samuel Fanta; Janne T Backman; Paula Seikku; Christer Holmberg; Kalle Hoppu
Journal:  Pediatr Nephrol       Date:  2005-03-17       Impact factor: 3.714

Review 3.  Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients.

Authors:  P Belitsky; S Dunn; A Johnston; G Levy
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

4.  Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates.

Authors:  S Fanta; S Jönsson; J T Backman; M O Karlsson; K Hoppu
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.